Chemesis International Inc. announces collaboration with Happy Tea
By Akshay Kedari  Date: 2019-07-16

Chemesis International Inc. announces collaboration with Happy Tea

The company will produce products of Happy Tea in its facilities based in the U.S. and will boost manufacturing as demand rises.

Chemesis International Inc. has reportedly announced that it has partnered with Happy Tea, a U.S. based provider of CBD infused shots and sachets. The partnership will allow Happy Tea to enlarge its product offering and cut costs by benefitting from Chemesis’ extraction, finished goods production and retail distribution.

Apparently, Happy Tea offers 3 products including flavored oil shots and powdered drink mixes which comprises a combination of all- antioxidants and -natural ingredients and are permeated with 10mg of CBD.  Customers can buy these products individually or subscribe to monthly deliveries, which are dispatched by e-commerce sales channels of the company throughout the United States. It will leverage multi-state operations of Chemesis to augment production capacities and build retail brick and mortar exposure through the company’s distribution.

Sources cited that Chemesis will help Happy Tea to expand its current 3 SKU’s to an extended 9 SKU’s product line. The company will produce products of Happy Tea in its facilities based in the U.S. and will boost manufacturing as demand rises. As per the partnership, Chemesis has received a $4,000,000 minimum purchase order to manufacture products and will get more orders with increase in demand. Also, the expansion of product catalogue, additional contracts of Happy Tea will be added to ensure sufficient supply. 

Jarrod Swanger, COO, Happy Tea, reportedly stated that the manufacturing and development capacities of Chemesis fits in-line with the goals of the company. With Chemesis’ capability and Happy Tea’s branding, the company has intended to own the CBD market, he further added.

Edgar Montero, CEO, Chemesis, reportedly noted that the company has been delighted to be working with Happy Tea, a developed brand which is currently in a high-growth phase. The products and vision of Happy Tea are something the company believes in and looks forward to supporting its long-term growth, he further noted.

 

Source credit: https://www.globenewswire.com/news-release/2019/07/15/1882367/0/en/Chemesis-International-Inc-Announces-Partnership-with-Happy-Tea.html

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...